Physiologic Process | Receptor | Arrestin | Proposed/Possible Effector Pathway(s) | References |
---|---|---|---|---|
Embryologic development | ||||
Hedgehog signaling | ||||
Hematopoiesis | Smootheneda | z-Arr2 | YY1 transcription factor | Yu et al., 2008 |
Embryo patterning | Smootheneda | z-Arr3 | Gli family transcription factors | Wilbanks et al., 2004 |
Retinal function | ||||
Autosomal dominant retinitis pigmentosa | Rhodopsin K296E | Arr1 | N.D. | Li et al., 1995 |
Photoreceptor cell apoptosis | Rhodopsin | d-Arr1 | RdgC-inhibition of caspase-dependent cell death | Alloway et al., 2000; Kiselev et al., 2000 |
Dopamine-dependent behaviors | ||||
Attenuation of dopamine-dependent hyperactivity | Dopamine D2 | Arr3 | Activation of GSK3β by arrestin3-PP2A-Akt complex | Beaulieu et al., 2004, 2005 |
Lithium and neuroleptic drug action | Dopamine D2 | Arr3 | Blockade of arrestin-dependent GSK3β activation | Beaulieu et al., 2008; Masri et al., 2008 |
Cardiovascular regulation | ||||
Cardiomyocyte hypertrophy; bradycardia | Angiotensin AT1a | N.D. | Src; ERK1/2; p90RSK | Zhai et al., 2005 |
Aldosterone secretion and volume retention | Angiotensin AT1a | Arr2 | ERK1/2; upregulated StAR expression | Lymperopoulos et al., 2009 |
Cardiomyocyte survival in heart failure | β1 adrenergic | Arr3 | Src-dependent EGF receptor transactivation | Noma et al., 2007 |
Vascular smooth muscle neointimal hyperplasia | N.D. | Arr3 | ERK1/2; EGF receptor transactivation; p90RSK-Akt | Ahn et al., 2009; Kim et al., 2008 |
Cutaneous vasodilation and flushing | GPR109A | Arr2 | cPLA2-prostaglandin D2 pathway activation | Walters et al., 2009 |
Skeletal remodelling | ||||
Stimulation of osteoblastic bone formation | PTH1 | Arr3 | N.D. | Gesty-Palmer et al., 2009 |
Immune system function | ||||
Allergen-induced Th2 lymphocyte chemotaxis | N.D. | Arr3 | N.D. | Walker et al., 2003 |
Inhibition of neutrophil chemotaxis | CXCR2 | Arr3 | N.D. | Su et al., 2005 |
Inhibition of chemotaxis and cytokine production | TLR4a | Arr3 | ERK1/2 activation; IκB-NFκB inhibition | Basher et al., 2008 |
Inhibition of NK cell cytotoxicity | KIR2DL1a | Arr3 | SHP-1, SHP-2 dependent signaling | Yu et al., 2008 |
Tumor growth and metastasis | ||||
Bladder cancer proliferation; migration; metastasis | Thromboxane TP-β | Arr3 | ERK1/2; FAK | Moussa et al., 2008 |
Breast cancer invasion; metastasis | LPA1; LPA2 | Arr2 | Ral, Ral-GDS mediated cytoskeletal rearrangement | Li et al., 2009 |
Ovarian cancer progression; metastasis | Endothelin ET-A | Arr2 | Src-EGF receptor-ERK1/2-Akt; GSK3β−β-catenin | Rosanò et al., 2009 |
Phorbol ester-induced papilloma formation | Prostaglandin EP2 | Arr2 | Src-EGF receptor-Ras-ERK1/2-Akt | Chun et al., 2009 |
Inhibition of tumor cell migration | TGFβ receptor IIIa | Arr3 | Activation of cdc42; Inhibition of NFκB | Mythreye and Blobe, 2009; You et al., 2009 |
Androgen-independent prostate cancer growth | Androgen receptora | Arr3 | Mdm2-dependent AR ubiquitination/degradation | Lakshmikanthan et al., 2009 |
Metabolic regulation | ||||
Increased insulin sensitivity | Insulin receptora | Arr3 | IR-Akt-Src complex assembly | Luan et al., 2009 |
z-, Zebrafish arrestin; d-, D. melanogaster arrestin; N.D., not determined.
↵a Non-GPCR.